The general manager of IMS Health, Zsolt Szepesházi, explains how the current limitations of Hungary’s healthcare system have shifted the way that…

Novo Nordisk Hungary GM Zsolt Jozsa highlights the growing prevalence of diabetes in Hungary, the gap in treatment options that the company is…

The managing director of Janssen Hungary, Andreas Woitossek, depicts the valuable role of real-world evidence in enabling the affiliate’s consistent…

With various new government measures, the pharmaceutical and healthcare sector in Hungary has been undergoing quite a turbulent period recently. But…

Hungary has been recognized as one of the largest pharmaceutical and healthcare markets in Central and Eastern Europe, and can obviously not be…

You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic…

The Hungarian pharmaceutical environment has been undergoing a turbulent time recently, with many new measures being implement by the Government. What…

With approximately $90 billion flowing into the country (according to the Hungarian Investment and Trade Agency) since it abolished its centrally…

Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already…

IMS is a strong brand name when it comes to pharma and healthcare information worldwide. Can you please elaborate on the particularities that set the…

The Hungarian pharmaceutical environment has been undergoing many changes recently, such as a sales tax increase to 20%. Do you feel this is a climate…

Hungary is one of the largest pharmaceutical markets in the region, and has been used by Janssen-Cilag as a hub. Can you elaborate on how important…